IRADIMED CORP Files 8-K for Material Definitive Agreement
Ticker: IRMD · Form: 8-K · Filed: Jun 3, 2024 · CIK: 1325618
Sentiment: neutral
Topics: material-definitive-agreement, filing
Related Tickers: IRMD
TL;DR
IRADIMED CORP signed a big deal, filing an 8-K. Details to follow.
AI Summary
On May 29, 2024, IRADIMED CORP entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. Specific details of the agreement and its financial implications are not fully disclosed in the provided text, but it is classified as a significant event requiring an 8-K filing.
Why It Matters
This filing indicates a significant business event for IRADIMED CORP, potentially impacting its operations, financial standing, or strategic direction.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant financial or operational implications, but the specifics are not yet detailed.
Key Players & Entities
- IRADIMED CORP (company) — Registrant
- May 29, 2024 (date) — Date of earliest event reported
- 001-36534 (company) — Commission File Number
- 73-1408526 (company) — IRS Employer Identification No.
- 1025 Willa Springs Dr. (address) — Principal executive offices
- Winter Springs, FL 32708 (address) — Principal executive offices
- 4076778022 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by IRADIMED CORP?
The provided text states that IRADIMED CORP entered into a material definitive agreement on May 29, 2024, but does not specify the details of the agreement.
What is the filing date of this 8-K report?
The filing date, also referred to as the 'AS OF DATE', is June 3, 2024.
What is IRADIMED CORP's principal executive office address?
IRADIMED CORP's principal executive office is located at 1025 Willa Springs Dr., Winter Springs, FL 32708.
What is the Commission File Number for IRADIMED CORP?
The Commission File Number for IRADIMED CORP is 001-36534.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported is May 29, 2024.
Filing Stats: 713 words · 3 min read · ~2 pages · Grade level 13.6 · Accepted 2024-06-03 08:30:17
Key Financial Figures
- $0.0001 — h registered: Common stock, par value $0.0001 IRMD NASDAQ Capital Market Item 1
- $34,133 — mendment, the monthly base rent will be $34,133, adjusted annually for changes in the c
Filing Documents
- irmd-20240529x8k.htm (8-K) — 37KB
- irmd-20240529xex99d1.htm (EX-99.1) — 27KB
- 0001558370-24-008847.txt ( ) — 183KB
- irmd-20240529.xsd (EX-101.SCH) — 3KB
- irmd-20240529_lab.xml (EX-101.LAB) — 15KB
- irmd-20240529_pre.xml (EX-101.PRE) — 10KB
- irmd-20240529x8k_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On May 29, 2024, IRADIMED CORPORATION, a Delaware corporation (the " Company "), entered into that certain Amendment to Susi, LLC Lease Agreement (the " Lease Amendment ") with SUSI, LLC, a Florida limited liability company(the " Landlord "), controlled by the Company's President, Chief Executive Officer, and Chairman of the Board, Roger Susi, which amended that certain Susi, LLC Lease Agreement (the " Lease "), dated as of January 17, 2014, related to the Company's manufacturing and headquarters facility in Winter Springs, Florida (the " Premises "). Under the Lease Amendment, the term of the Lease was extended an additional one year and now expires on May 31, 2025 (the " Lease Extension "). Subject to prior written notice to the Landlord given not later than 30 days prior to the expiration of the Lease, the Company may remain in possession of the Premises on a month-to-month basis, for an aggregate period not to exceed six months (the " Monthly Tenancy "). The Monthly Tenancy automatically will continue on a monthly basis for each successive month following expiration of the Lease Extension, and will terminate on the earlier of (a) the last day of the calendar month designated in the Company's written notice to the Landlord terminating the Monthly Tenancy, given at least 15 days prior to the designated termination date, and (b) November 30, 2025. Pursuant to the terms of the Lease Amendment, the monthly base rent will be $34,133, adjusted annually for changes in the consumer price index. Under the terms of the Lease, the Company is responsible for insurance and maintenance expenses. The foregoing description of the Lease Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Lease Amendment, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Amendment to Susi, LLC Lease Agreement, dated May 29, 2024, by and between IRADIMED CORPORATION and SUSI, LLC. 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IRADIMED CORPORATION Date: June 3, 2024 By: /s/John Glenn Name: John Glenn Title: Chief Financial Officer